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Abstract
Vitamin K antagonists, such as warfarin, have a narrow therapeutic window; patients on these therapies therefore require regular
international normalized ratio (INR) monitoring to maintain optimal dosing. This involves periodic checks and laboratory testing
using venepuncture, which are often perceived as a burden. This study aimed to determine the accuracy and precision of the
LumiraDx INR Test, a new point-of-care in vitro diagnostic platform, in an anticoagulation clinic setting. In this observational,
cross-sectional study, precision of the LumiraDx INR Test was assessed using paired replicate samples (n ¼ 366) and 3 test strip
lots. Accuracy was determined by comparing capillary blood INR, ascertained by the LumiraDx INR Test, with venous plasma
INR, measured by the laboratory reference instrument, the IL ACL ELITE Pro. Furthermore, INR was assessed across a range of
hematocrit (25%-55%). In addition, feedback was collected from health-care professionals via a self-completed questionnaire. This
trial was registered at ClinicalTrials.gov (NCT03682419). The precision (% coefficient of variation) of the LumiraDx INR Test was
<4 when samples were applied by direct application or via a capillary transfer pipette, as well as between test strip lots. Accuracy
of the LumiraDx INR Test, across the INR range of 0.8 to 7.5, was confirmed by a strong correlation of 0.965 (95% confidence
interval: 0.959-0.970) when compared with the IL ACL ELITE Pro, which was maintained across the hematocrit range. Feedback
from health-care professionals indicated that the instructions given by the system were easy to follow. In conclusion, the strong
agreement between the LumiraDx Platform INR point-of-care test and the IL ACL ELITE Pro laboratory reference system, as well
as between the different application methods and test lots, indicates that it can provide a rapid, accurate, and reliable INR analysis.
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Introduction
Vitamin K antagonists (VKA) oral anticoagulation therapies,
such as warfarin, have been used in primary and secondary care
for more than 60 years, and both the short-term and long-term
effects in patients have been well established.1 VKAs are
guideline-recommended drugs for the treatment of venous
thromboembolism (VTE), the prevention of thrombotic events
(TEs) in patients with atrial fibrillation (AF), and the manage-
ment of patients with mechanical heart valves.2-4 One of the
main disadvantages of VKA therapy is the narrow therapeutic
window; the effectiveness of treatment, to prevent bleeding
complications or TEs, is highly dependent on dose
management. The anticoagulant effect of VKAs must be
closely monitored using the international normalized ratio
(INR) as standard, to typically maintain patients with VTE and
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AF within an INR target range of 2.0 to 3.0 and patients with
mechanical heart valves within the target range of 2.5 to 3.5.2,5
INR values are derived from the international sensitivity
index, which is calculated as a ratio of the patient’s prothrom-
bin time (PT) to a control PT with the assay method and reagent
standardized by the World Health Organization (WHO) stan-
dard.6,7 Dose management of VKA therapy is challenging as an
INR can be affected by the patient’s genetic background,
comorbid conditions, other drug interactions, and lifestyle.6,7
To assess the effectiveness of VKA therapy for a given patient,
the time in therapeutic range (TTR) has become a standard
measure; TTR represents the percent of time the INR remains
within target range across time.8 The prerequisite to optimal
VKA therapy using TTR is to ensure the correct assessment of
a patient’s INR, which is dependent on high accuracy and pre-
cision of the method and device used.9
There are multiple factors that can affect INR control, such
as vitamin K supplementation, drug interactions, and alcohol
consumption.10 Therefore, patients on VKA treatment must
undergo periodic checks (in our local anticoagulant service,
the average time between testing is 23 days)—these periodic
checks and laboratory testing using venipuncture are often per-
ceived as a burden.3,11-13 However, the monitoring of patients
receiving VKA treatment has been greatly assisted by the intro-
duction of point-of-care (POC) coagulometers for analyzing
INR using small volumes of capillary whole blood, at the
patient side.14 The VKA therapy can be managed in different
care settings, such as at the general practitioner’s office, hos-
pital outpatient clinics, and specialized anticoagulation clinics,
but also in the patient’s home through patient self-testing and
patient self-management.9 The POC coagulometers used in a
clinical setting enable rapid clinical decision-making, by pro-
viding quicker turnaround time compared with laboratory test-
ing.14 From a quality control perspective, the comparison of
POC coagulometers with a gold-standard laboratory reference
method is paramount to assure accuracy and precision and to
keep within the narrow therapeutic range of VKA drugs.9
The LumiraDx Platform is a POC system designed for the
measurement of multiple parameters near the patient using
small volume blood sampling methods, such as capillary blood
from fingersticks. The objective of this study was to evaluate
the accuracy and precision of the new LumiraDx Platform INR
Test in a POC setting using both direct application and pipette
transfer of capillary blood to the test strips for potential inclu-
sion in future routine clinical practice.
Methods
Study Population and Sample Preparation
This study was conducted at 11 anticoagulation clinical sites
across the Glasgow and Clyde and Lanarkshire regions (Glas-
gow Royal Infirmary, Glasgow, United Kingdom; Queen Eli-
zabeth University Hospital, Glasgow, United Kingdom;
Golden Jubilee National Hospital, Glasgow, United King-
dom; University Hospital Hairmyres, East Kilbride, United
Kingdom; Airdrie Community Health Centre, Airdrie, United
Kingdom; Central Health Centre, Cumbernauld, United King-
dom; Central Health Centre, Hamilton, United Kingdom; Kil-
syth Community Health Centre, Kilsyth, United Kingdom;
Motherwell Health Centre, Motherwell, United Kingdom;
Stonehouse Hospital, Stonehouse, United Kingdom; Wishaw
Health Centre, Wishaw, United Kingdom). All anticoagula-
tion sites were provided with posters with contact numbers so
that patients who wanted to participate in the study could find
out further details and sign-up. The poster was also printed
and handed out to patients as a flyer at anticoagulation clinics.
In addition, several different recruitment methods were used
across the sites (ie, patient invitations were sent out, nurses
and other health-care providers recruited patients for direct
testing and subsequent appointments at anticoagulation
clinics, and some patients were prescreened for eligibility
based on anticoagulation lists).
Venous whole blood samples were analyzed at the labora-
tory of LumiraDx UK Ltd in Stirling, United Kingdom. The
study protocol complied with the Declaration of Helsinki
(2013) and was approved by the East of Scotland Research
Ethics Service (REC reference number: 17/ES/0161). All par-
ticipants gave written informed consent for POC and labora-
tory testing. This trial was registered at ClinicalTrials.gov
(NCT03682419).
A total of 420 participants were enrolled in the study
between September and November 2018. Of these, 394
received VKA therapy (warfarin), and a further 26 individu-
als—who fulfilled the study inclusion criteria but did not
receive VKA therapy—were included in order to test the lower
limits of detection of the LumiraDx INR Test. All participants
were aged older than 18 years and deemed medically appropri-
ate for study participation by the investigator (eg, patients with-
out known inherited [eg, hemophilia or von Willebrand
disease] or acquired [eg, liver cirrhosis] conditions that are
likely to be associated with a coagulopathy; or patients receiv-
ing non-VKA anticoagulant medication). Individuals were
excluded if they had previously participated in this study, were
within the first 4 weeks of receiving VKA therapy (since most
patients are initiated on warfarin using a slow induction proto-
col and will rarely achieve therapeutic INR levels during the
first few weeks of treatment), or had confirmed or suspected
pregnancy. A detailed list of eligibility criteria can be found in
the Supplementary Material.
Trained clinical staff obtained 2 fingerstick samples of
capillary blood from the patients, which were applied directly
to test strips for immediate duplicate measurements of INR on
the LumiraDx Platform; 2 similar fingerstick measurements
were performed using application via capillary transfer pip-
ettes. If the blood sample was inadequate (eg, an insufficient
volume of blood), the LumiraDx INR Test showed an error on
the screen. During the same study visit, venous whole blood
was collected in 2 anticoagulation collection tubes; one whole
blood tube was used for 2 measurements of hematocrit on the
HemoCue Hb 201þ, the second whole blood tube was pro-
cessed to plasma for subsequent measurement of INR with the
2 Clinical and Applied Thrombosis/Hemostasis
IL ACL ELITE Pro (Instrumentation Laboratory, Bedford,
MA) laboratory reference system. The IL ACL ELITE Pro used
the lyophilized recombinant thromboplastin, HemosIL, Read-
iPlasTin (Instrumentation Laboratory, Lexington, MA).
Investigative Device
The LumiraDx INR Test is an in vitro diagnostic medical test
that is used to provide INR based on quantitative PT of capil-
lary whole blood. The test is intended for professional POC use
for the monitoring of patients on anticoagulation therapy with
VKA drugs. The LumiraDx INR Test is a thrombin activation
assay in which a quenched substrate is cleaved by thrombin and
the emitted fluorescence is detected and quantified. When a
blood sample is applied to the test strip, coagulation is activated
by the recombinant thromboplastin, HemosIL, ReadiPlasTin (a
derivative of RecombiPlastin 2G, containing tissue factor and
phospholipids). Coagulation proceeds naturally in the presence
of ReadiPlasTin converting prothrombin to thrombin, which
subsequently recognizes a peptide sequence on the substrate
(Rhodamine). Following cleavage of this peptide sequence, the
substrate becomes unquenched and emits a fluorescent signal
detectable by the LumiraDx instrument. The amount of signal
detected over a specific time is converted by means of an
algorithm into INR and the result is displayed on the touch
screen. The INR test results are displayed in 60 to 90 seconds.
The LumiraDx INR Test was calibrated using the WHO inter-
national standard rTF/09 to provide traceability to reference
systems and the LumiraDx INR Test. A complete description
of the LumiraDx Platform and INR test can be found at the
LumiraDx website.15
Determination of Precision, Accuracy, and Overall
Agreement
Precision was measured by correlating duplicate repeated mea-
surements of samples that were either directly applied to the
test strips or applied using transfer pipettes. Three test strip lots
were used to complete the study. The accuracy of the Lumi-
raDx INR Test using capillary whole blood was assessed by
comparing test results with paired venous plasma samples mea-
sured using the IL ACL ELITE Pro. The accuracy of the Lumi-
raDx INR Test was assessed across the range of hematocrit
25% to 55% (as measured by HemoCue Hb 201þ System
[HemoCue]) using venous whole blood.
Professional User Acceptability Questionnaire
A questionnaire consisting of 29 questions was completed by
the health-care professionals who were involved in testing at
each of the sites of the study, which was intended to assess the
ease of use of the LumiraDx INR Test using a 5-point scale (1
¼ agree strongly, 2 ¼ agree somewhat, 3 ¼ neither agree nor
disagree, 4 ¼ disagree somewhat, and 5 ¼ disagree strongly;
Supplementary Material).
Statistical Analysis
Statistical analysis was performed using R version 3.5.1. The
precision of the INR measurements performed on the Lumi-
raDx Platform (samples applied directly or via transfer pip-
ettes) was calculated using the mean paired replicate %
coefficient of variation (%CV); an analytical variability of
5% CV was considered high precision.16,17 A Passing-
Bablok regression analysis was used to compare the INR
results with results of the IL ACL ELITE Pro reference instru-
ment to determine the accuracy of the LumiraDx INR Test. The
Food and Drug Administration (FDA)–recommended accuracy
standards were reviewed at a workshop in March 2016.18 The
FDA recommends that 95% of samples in the INR range from
2.0 to 4.5 should fall within 20% of the reference method and
25% above an INR of 4.5. The accuracy of INR measurements
across the range of hematocrit was assessed using linear
regression analysis.
Results
A total of 420 patients were enrolled in this study across the
research sites. Of these, 54 patients were excluded for the fol-
lowing reasons: transposition error when processing samples
(n ¼ 2); being deemed medically inappropriate by the investi-
gator (n¼ 1); retrospective exclusion by not meeting the inclu-
sion criteria due to a diagnosis of hemophilia A (factor VIII
deficiency; n ¼ 1); instrument software update rendering data
collected earlier unusable (n¼ 6); and recalibration of the ACL
ELITE Pro reference system meant that paired samples of
capillary blood and venous plasma were incomplete and
method comparison analysis not possible (n ¼ 44). The INR
results from 366 individuals (45% female), with a mean age of
69 years (range, 29-94 years) were included in the analysis,
which consisted of a population in receipt of VKA treatment
(all on warfarin; n¼ 340; median INR 2.48, interquartile range
[IQR]: 2.07-3.02) and a population without VKA treatment (n
¼ 26; median INR 0.92, IQR: 0.90-0.94). The demographics of
the 2 study populations and an analysis of reference INR values
are listed in Table 1. Of the 366 patients whose data were
included, complete sample sets were not always collected due
to patient sampling errors or patients unable to provide all
requested blood samples.
The precision of the LumiraDx INR Test was calculated
using the mean paired replicate %CV. The means of each of the
3 test strip lots demonstrate that the %CV was 4 (lot 5000003,
n¼ 167, mean INR 2.42, mean %CV 3.53; lot 5000004, n¼ 219,
mean INR 2.65, mean %CV 3.71; lot 5000006, n ¼ 189, mean
INR 2.49, mean %CV 3.52), indicating a high precision of mea-
surements of the different test strip lots (Table 2). Further analysis
showed that the analytical variability between different applica-
tion methods, that is, direct application and via capillary transfer
pipette, was 4%CV (direct application, n ¼ 284, mean INR
2.54, mean %CV 3.46; transfer pipette, n ¼ 291, mean INR
2.53, mean %CV 3.73). This indicates that the sample application
area on the test strip is capable of accepting fingerstick blood
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samples with high precision directly from a fingertip or using the
capillary transfer tube (Table 3).
The accuracy of the LumiraDx INR Test was assessed by
correlating the INR measurements of capillary whole blood
to the venous plasma samples measured by the IL ACL
ELITE Pro reference instrument. The INR results of directly
applied samples (n ¼ 596) demonstrated a strong correlation
with the IL ACL ELITE Pro across the INR range 0.8 to 7.5
(r ¼ 0.965; 95% confidence interval [CI]: 0.959-0.970; Fig-
ure 1). In addition, a strong correlation was measured when
using capillary transfer pipettes (n ¼ 598; r ¼ 0.958; 95%
CI: 0.950-0.964) for the application of blood samples to the
test strip (Table 4). Further analysis was completed accord-
ing to the FDA-recommended accuracy standards. Results
from the LumiraDx INR Test were compared to the IL ACL
ELITE Pro and were grouped by INR range. For INR 2.0 to
4.5, 98.6% of LumiraDx direct application samples, and
97.7% of samples using the capillary transfer pipette, were
within 20% of the IL ACL ELITE Pro. For INR >4.5, 100%
of LumiraDx direct application samples and capillary trans-
fer pipette were within 25% of the IL ACL ELITE Pro.
Therefore, results showed good agreement with FDA-
proposed accuracy standards.
The accuracy was further assessed by the relationship of the
difference in INR measurements between the LumiraDx INR
Test and the IL ACL ELITE Pro, across the range of hematocrit
measured by the Hemocue Hb 201þ. Results demonstrated that
accuracy was maintained across the hematocrit range of 25% to
55% (data not shown).
Overall, feedback from health-care professionals indicated
that the instructions on sample collection and application and
pretest procedures were easy to follow (mean score of respon-
dents: 1.67 and 1.75, respectively); the display showed clear,
easy-to-read results (mean scores of respondents: 1.67); and the
system was easy to prepare (mean score of respondents: 1.75)
and was simple to clean (mean scores of respondents: 2.08).
Table 1. Demographic Data Relating to Age and Sex of Recruited Individuals.a
VKA Sex n
Age INR (IL ACL ELITE Pro)
Mean Min Max Median First Quartile Third Quartile INR Max
Warfarin Female 146 70 37 92 2.55 2.09 3.10 5.66
Male 194 71 30 94 2.45 2.07 2.88 7.51
Combined 340 71 30 94 2.48 2.07 3.02 7.51
No anticoagulant therapy Female 17 54 29 81 0.93 0.90 0.94 1.03
Male 9 51 35 77 0.92 0.91 0.93 1.03
Combined 26 53 29 81 0.92 0.90 0.94 1.03
Abbreviations: INR, international normalized ratio; VKA, vitamin K antagonist.
aA subpopulation of 26 individuals not receiving VKA treatment was included in this study in order to test the lower limits of detection of the LumiraDx INR Test.
Table 2. Precision of INR Measurements Using 3 Test Strip Lots.a
Lot # n (Duplicates) Mean INR Mean %CV
5000003 167 2.42 3.53
5000004 219 2.65 3.71
5000006 189 2.49 3.52
Combined 575 2.53 3.60
Abbreviations: CV, coefficient of variation; INR, international normalized ratio.
aCapillary whole blood samples were measured in duplicate. Three different
test strip lots were used across the study. The data consist of capillary blood
applied directly to the test strip or via a transfer pipette.
Table 3. Precision of Mean INR Measurements of Samples Directly
Applied to the Test Strip or by Method Involving a Transfer Pipette.a
Method n (Duplicates) Mean INR Mean %CV
Direct application 284 2.54 3.46
Transfer pipette 291 2.53 3.73
Abbreviations: CV, coefficient of variation; INR, international normalized ratio.
aCapillary whole blood samples were applied to the test strip either by direct
application or using transfer pipettes, and INR was measured in duplicate by
the LumiraDx instrument.
Figure 1. Scatter plot graph illustrating the correlation of INR mea-
surements between the LumiraDx INR Test and the IL ACL ELITE Pro
reference instrument. The INR measurements of directly applied fin-
gerstick capillary whole blood as assessed by the LumiraDx INR Test
were correlated with the venous plasma INR assessed by the IL ACL
ELITE Pro.
Abbreviations: INR, international normalised ratio; Int CI, intersection
confidence interval; Slp CI, slope confidence interval.
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Furthermore, feedback indicated that additional training was
required for the health-care professionals beyond the user man-
ual in the application of samples to the test strips and on how to
resolve errors (Figure S1).
Discussion
This observational, cross-sectional study was conducted to
evaluate the accuracy and precision of the new LumiraDx Plat-
form INR Test in comparison with a gold-standard laboratory
reference instrument, the IL ACL Elite Pro. The INR results of
366 patients, tested in multiple clinical settings, showed that
the LumiraDx INR Test correlated well with laboratory testing,
as well as between the different application methods and test
strip lots. Feedback from health-care professionals indicated
that the instructions of the LumiraDx INR Test were easy to
follow, results were displayed clearly and were easy to read,
and the system was easy to prepare and clean. Overall, based on
the tests performed, the LumiraDx Platform INR test provides
reliable INR analysis of patients who are on VKA therapy
when used by health-care professionals at the POC.
Conventional laboratory methods for testing INR require
plasma samples separated from whole blood by centrifugation.
This entails venipuncture performed by a phlebotomist, sample
transport and handling, and testing performed by a skilled
laboratory technician, which adds to turnaround time and work-
load.16 The introduction of POC INR tests has offered signif-
icant advantages for clinicians and patients. For example, the
tests can be performed by non-laboratory-trained clinical staff
at the site of the patient, with results available in minutes,
which considerably reduces the time from test performance
to test result and diagnosis. Patients on VKA anticoagulants
require regular monitoring of their INR. The use of POC INR
test systems in community-based anticoagulation clinics or in
patients’ homes by trained health-care professionals could
minimize discomfort by reducing traveling time to a hospital
for venous blood draw by a phlebotomist. Furthermore, it can
provide direct access to fast results and any required changes to
the treatment plan. Moreover, POC testing can measure INR in
drops of capillary whole blood obtained by fingerstick (*10 mL
per sample), which is more convenient for the patient.11,16
Although the introduction of direct oral anticoagulants
(DOACs) has meant that clinicians have a wider choice of
drugs for the treatment of VTE and the prevention of TEs in
patients with AF, there remains a significant group of patients
for whom DOACs are unsuitable (eg, mechanical heart valves,
renal impairment, interacting drugs). In such patients, VKA
treatment is the only alternative and it can be contended that
VKA treatment will continue to remain an important option for
many patients in the future. Therefore, improving benefit–risk
ratios, as well as the technology of POC systems in terms of
ease of use, speed, cost, accessibility, and analytical and clin-
ical accuracy, is paramount for improving clinical outcomes.2
Limitations
This study uses a robust and recognized study design to provide
clear results on the objectives. However, we recognize some
important limitations. Health-care professionals had different
opinions on a number of points in the questionnaire, regarding
the simplicity of applying adequate patient samples to the INR
test strips, the requirement of additional training, and on how to
resolve errors. Following the completion of this study, the
manufacturer addressed these points with improved training
videos on “sample collection and application” and “how to run
a test.” These can be found on the LumiraDx website
(https://kc.lumiradx.com/us-en/platform-training/videos) and
are also provided to health-care professionals for further train-
ing. In addition, further information on test errors has been
made available in the user manual. Subsequent evaluations
have shown that the application of a sample to the test strip
is no longer an issue for users.
A study weakness for ease-of-use evaluation was that
health-care professionals in the study were very experienced
in a different INR POC method and therefore were more profi-
cient in the method they made the comparison to. Although
they perceived that the alternative method was faster, in fact the
2 methods are very similar (CoaguCheck Pro II: INR results in
9.6-96 seconds, and LumiraDx INR Test: INR results in 60-90
seconds).15,19 To improve the experience of the health-care
professionals, additional training has been implemented.
Patient experience in this study was based on health-care pro-
fessional perception and not actual patient feedback; this will
be addressed in a future study.
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